Extended Data Fig. 6: Albumin nanoparticles of the dual targeting compound (Nano-273) extend survival in KPC transgenic and syngeneic mouse models. | Nature Cancer

Extended Data Fig. 6: Albumin nanoparticles of the dual targeting compound (Nano-273) extend survival in KPC transgenic and syngeneic mouse models.

From: Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer

Extended Data Fig. 6: Albumin nanoparticles of the dual targeting compound (Nano-273) extend survival in KPC transgenic and syngeneic mouse models.The alternative text for this image may have been generated using AI.

(a) Antitumor efficacy in transgenic KPC (LSL-KrasG12D, LSL-Trp53R172H, Pdx1cre/+) PDAC mice with different treatments. Survival rate of KPC mice after treatment with Paclitaxel in albumin nanoformulation (i.v., 11.7 μmol/kg) and IPI-549 (i.p., 28.4 μmol/kg) plus anti-PD1 antibody (100 µg, i.p.), MSA-2 (oral dose, 204 μmol/kg) and IPI-549 (oral dose, 28.4 μmol/kg) plus anti-PD1 antibody (100 µg, i.p.) and SH-273 (i.v., 17.6 μmol/kg) plus anti-PD1 antibody (100 µg, i.p.). The experiments are conducted at the same time with Fig. 7a with different groups (Nano-P + IPI-549+anti-PD-1, MSA-2 + IPI-549+anti-PD-1 and SH-273+anti-PD-1) for comparison. (b) Antitumor efficacy in C57BL/6 mice inoculated with KPC 6422 tumor after different treatments. Individual tumor volume after treatment with PBS (control), MSA-2 (i.v., 34.0 μmol/kg) with or without anti-PD1 antibody (i.p., 100 µg), Nano-273 (i.v., 17.6 μmol/kg) with or without anti-PD1 antibody (i.p., 100 µg). (c, d) The serum concentration of IL35, IL10 and IL27 (c) and IFNβ and TNF (d) of syngeneic C57BL/6 mice subcutaneous inoculated with KPC 6422 tumor after treatment with PBS (control), MSA-2 (i.v., 34.0 μmol/kg) with or without anti-PD1 antibody (100 µg, i.p.), Nano-273 (i.v., 17.6 μmol/kg) with or without anti-PD1 antibody (100 µg, i.p.). (e) Antitumor efficacy in syngeneic pancreatic cancer (KPC 6422 cell line) model with different treatments. Average and individual tumor volume after treatment with PBS (control), MSA-2 (i.v., 34.0 μmol/kg) plus anti-PD1 antibody (100 µg, i.p.), SH-273 (i.v., 17.6 μmol/kg) plus anti-PD1 antibody (100 µg, i.p.) or Nano-273 (i.v., 17.6 μmol/kg) plus anti-PD1 antibody (100 µg, i.p.). (f) Quantification flow cytometry analysis of IL-35+ (Ebi3+) and IL-10+ Breg cells at tumor and lymph node in mice from antitumor efficacy study at (e). The data represents two (c-f) or three (a, b) independent experiments with mean ± SD, and n = 3 biologically independent samples (f), n = 4 biologically independent samples (c, d), n = 5 mice (e) and n = 10 mice (a, b). Statistical comparisons are based on log-rank (Mantel–Cox) test (a) one-way analysis of variance (f), or two-way analysis of variance (c, d, e). P values are indicated.

Source data

Back to article page